KKR launched Allyntra, a precision-engineered solutions platform, to serve the medical technology and high-precision industrial markets by building on its investment in Precipart. Meanwhile, KKR is reportedly exploring a potential takeover of Qiagen alongside other private equity firms, causing Qiagen's shares to surge. Additionally, Spero Therapeutics shares declined following the announcement of a $105 million funding agreement with KKR.
Global investment firms KKR and AEW are reportedly looking to sell property assets in China as the sector continues to face significant headwinds.
Read the full storySpero Therapeutics shares fell after securing a $105 million funding agreement with KKR, as investors weighed the capital injection against potential dilution.
Reports of early-stage interest from EQT, Advent, and KKR in the German diagnostics firm have triggered a surge in its share price.